Baidu
map

折叠错误的蛋白质会在健康小鼠中引起帕金森样疾病

2012-11-20 佚名 美国科学促进会

  新的研究可能有助于厘清帕金森氏病研究中的一个有争议的问题,即有关异常“α-突触核蛋白”在这种疾病中扮演的角色。科学家们如今报告说,将这些折叠错误的蛋白注射到健康小鼠的脑中会引起帕金森氏病的主要症状。这些异常蛋白团块在神经元内的积聚是帕金森氏病和其它相关疾病的标志。这些团块被称作路易体(Lewy bodies)和路易神经突(Lewy neurites),它们与黑质致密部(SN

  新的研究可能有助于厘清帕金森氏病研究中的一个有争议的问题,即有关异常“α-突触核蛋白”在这种疾病中扮演的角色。科学家们如今报告说,将这些折叠错误的蛋白注射到健康小鼠的脑中会引起帕金森氏病的主要症状。这些异常蛋白团块在神经元内的积聚是帕金森氏病和其它相关疾病的标志。这些团块被称作路易体(Lewy bodies)和路易神经突(Lewy neurites),它们与黑质致密部(SNpc)和其它脑区域中某些神经元的大量流失有关。但是,在路易体/神经突的形成与神经元退行性病变之间是否有一种因果关系则仍然不清楚。令情况更为复杂的是,无论是转基因或是基于神经毒素的帕金森氏病的动物模型都无法充分产生该病在人体中造成的结果。Kelvin Luk及其同事将产自重组小鼠α-突触核蛋白的合成α-突触核蛋白原纤维注射到正常小鼠的脑中。他们发现,折叠错误的α-突触核蛋白引起了帕金森氏病样的路易体和神经突的形成,以及随后的,包括黑质致密部(SNpc)在内的,大脑内相连接的各个区域中异常α-突触核蛋白的细胞至细胞的传输。这些结果导致了多巴胺能神经元的进行性丧失,并以那些类似帕金森氏病的运动缺失而告终。由此看来,异常的α-突触核蛋白确实在帕金森氏病的发展中扮演着一种致病性的角色。



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1765489, encodeId=d9581e654897a, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Dec 16 02:29:00 CST 2012, time=2012-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032006, encodeId=3a0c203200613, content=<a href='/topic/show?id=99324851204' target=_blank style='color:#2F92EE;'>#帕金森样疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48512, encryptionId=99324851204, topicName=帕金森样疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Jan 27 06:29:00 CST 2013, time=2013-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296865, encodeId=fc5c129686571, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Nov 22 04:29:00 CST 2012, time=2012-11-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1765489, encodeId=d9581e654897a, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Dec 16 02:29:00 CST 2012, time=2012-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032006, encodeId=3a0c203200613, content=<a href='/topic/show?id=99324851204' target=_blank style='color:#2F92EE;'>#帕金森样疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48512, encryptionId=99324851204, topicName=帕金森样疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Jan 27 06:29:00 CST 2013, time=2013-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296865, encodeId=fc5c129686571, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Nov 22 04:29:00 CST 2012, time=2012-11-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1765489, encodeId=d9581e654897a, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Dec 16 02:29:00 CST 2012, time=2012-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032006, encodeId=3a0c203200613, content=<a href='/topic/show?id=99324851204' target=_blank style='color:#2F92EE;'>#帕金森样疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48512, encryptionId=99324851204, topicName=帕金森样疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Jan 27 06:29:00 CST 2013, time=2013-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296865, encodeId=fc5c129686571, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Nov 22 04:29:00 CST 2012, time=2012-11-22, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map